Better Days Ahead? Opportunities to Improve Care for Patients with IBD: A Focus on New and Emerging Therapies

 

 

Release date: June 29, 2021
Expiration date: June 29, 2022
Estimated time to complete activity: 105 minutes

 

PROVIDER STATEMENT

Provided by Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from AbbVie Inc.

FACULTY

Aline Charabaty, MD, AGAF, FACG (Chair)
Assistant Clinical Director, Division of Gastroenterology
Johns Hopkins School of Medicine
Johns Hopkins – Sibley Memorial Hospital
Washington, District of Columbia

Marla C. Dubinsky, MD
Professor of Pediatrics and Medicine
Chief, Pediatric GI and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Center
Mount Sinai Hospital Kravis Children’s Hospital
Icahn School of Medicine, Mount Sinai New York
New York, New York

Dana Lukin, MD, PhD, AGAF, FACG
Clinical Director of Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
Associate Professor of Clinical Medicine
Director, Advanced Fellowship Program in IBD
New York Presbyterian Hospital – Weill Cornell Medicine
New York, New York

PROGRAM OVERVIEW

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease, reduces patients’ quality of life and is associated with substantial medical, financial, and social burdens. More than 3 million people in the US and Europe are estimated to have IBD. Despite recent advances in therapies, clinicians are still faced with challenges in treating and managing their patients with IBD. Clinicians must choose from a vast array of agents in a variety of drug classes with different mechanisms of action, including agents that are newly available or under clinical investigation. In view of this expansion of therapeutic options, it is crucial for clinicians to remain current regarding all potential treatment strategies to ensure optimal patient outcomes.

TARGET AUDIENCE

This program is intended for IBD specialists, gastroenterologists, gastroenterologists in training, surgeons, subspecialists including dieticians and psychologists, nurse practitioners, physician assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Apply safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management
  • Analyze potential approaches for positioning new and emerging therapies for UC
  • Evaluate complex clinical situations in which patients with IBD may benefit from management strategies, including novel therapies
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of June 29, 2021 through June 29, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

PHYSICIAN CONTINUING EDUCATION

 

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aline Charabaty, MD, AGAF, FACG
Consulting Fees: AbbVie, Janssen, Pfizer, Takeda

Marla C. Dubinsky, MD
Consulting Fees: AbbVie, Amgen, Arena, Boehringer Ingelheim, Celgene, Cornerstones Health, Eli Lilly, Genentech, Gilead, Janssen, Merck, Pfizer, Prometheus Biosciences, Projections Research, Rebiotix, Takeda, Target PharmaSolutions
Contracted Research: AbbVie, Janssen, Prometheus Biosciences
Ownership Interest/Co-Founder: MiTest Health, Trellus Health

Dana Lukin, MD, PhD, AGAF, FACG
Consulting Fees: Abgenomics, AbbVie, Palatin Technologies, Pfizer, Takeda
Contracted Research: AbbVie, Janssen, Kenneth Rainin Foundation, Takeda

The Integrity Continuing Education planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

 

Continue to Pretest